Market Place
Sourcing Support
Summit Therapeutics Raises $500 Million In Private Placement
22 Oct 2025 //
BUSINESS WIRE
Summit Targets 2025 FDA Application For Ivonescimab Post
21 Oct 2025 //
BIOSPACE
Akeso, Summit PD-1/VEGF Blocker Exceeds Survival Expectations
20 Oct 2025 //
BIOSPACE
Summit Pharma Updates Q3 Financials And Operational Progress
20 Oct 2025 //
BUSINESSWIRE
Akeso, Summit`s Ivonescimab Beats PD-1 In Chemo Combo In 1L NSCLC
19 Oct 2025 //
FIERCE BIOTECH
Summit Expands Ivonescimab Phase III To Include Harmoni-Gi3 Study
17 Oct 2025 //
BUSINESSWIRE
Summit Pharma Hosts ESMO Data Update & Q3 Earnings Call On Oct
15 Oct 2025 //
BUSINESSWIRE
HARMONi-6 Ivonescimab + Chemo Vs Tislelizumab In 1L NSCLC At ESMO
24 Sep 2025 //
BUSINESSWIRE
Summit Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
24 Sep 2025 //
BUSINESSWIRE
Summit`s Keytruda Rival Faces US Approval Hurdles Due to Issues
08 Sep 2025 //
BIOSPACE
Ph 3 HarmonI Trial: Ivonescimab Plus Chemo Improves Survival
07 Sep 2025 //
BUSINESSWIRE
Summit Therapeutics to Host Update Call at WCLC 2025 on Sept 8
03 Sep 2025 //
BUSINESSWIRE
Ivonescimab Ph 3 HARMONi Data to Be Presented at WCLC 2025
14 Aug 2025 //
BUSINESSWIRE
Summit Skips Investor Call Amid Deal Rumors
12 Aug 2025 //
FIERCE PHARMA
Summit Therapeutics` Q2 Financial Results & Operational Progress
11 Aug 2025 //
BUSINESSWIRE
Summit, Astrazeneca in Talks Over 15 B Cancer Drug Licensing Deal
05 Jul 2025 //
REUTERS
Revolution Medicine, Summit to Test RAS Inhibitor Combo in Cancer
30 Jun 2025 //
GLOBENEWSWIRE
Summit Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
06 Jun 2025 //
BUSINESSWIRE
Summit Therapeutics at 46th Annual Goldman Sachs Conference
05 Jun 2025 //
BUSINESSWIRE
Summit Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
16 May 2025 //
BUSINESSWIRE
Summit Therapeutics Reports Q1 Financial Results and Progress
01 May 2025 //
BUSINESSWIRE
Summit stock drops on Akeso bispecific OS data vs. Keytruda
25 Apr 2025 //
FIERCE PHARMA
Summit Therapeutics to Host Q1 2025 Results Call on May 1, 2025
24 Apr 2025 //
BUSINESSWIRE
Summit’s Beats Yet Another Cancer Med, Pressuring Keytruda
24 Apr 2025 //
BIOSPACE
Summit Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Apr 2025 //
BUSINESSWIRE
Summit Therapeutics Reports Inducement Grants Under Nasdaq 5635(c)(4)
21 Mar 2025 //
BUSINESSWIRE
Robert LaCaze Joins Summit As Chief Commercial Officer
17 Mar 2025 //
BUSINESSWIRE
Summit Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
14 Mar 2025 //
BUSINESSWIRE
Summit Reports Q4, Full-Year 2024 Results & Operational Progress
24 Feb 2025 //
BUSINESSWIRE
Akeso Highlights Summit Therapeutics and Pfizer Collaboration
24 Feb 2025 //
PR NEWSWIRE
Pfizer to explore ADCs combo with Summit`s PD-1/VEGF bispecific
24 Feb 2025 //
BUSINESSWIRE
Summit Therapeutics to Host Q4 & Full Year 2024 Financial Results
18 Feb 2025 //
BUSINESSWIRE
Summit Therapeutics Reports Inducement Grants Under Nasdaq LR
14 Feb 2025 //
BUSINESSWIRE
Summit Therapeutic Report Inducement Grants Under Nasdaq 5635(c)(4)
16 Jan 2025 //
BUSINESSWIRE
Summit Therapeutics To Present At 43rd Annual JP Morgan Conference
07 Jan 2025 //
BUSINESSWIRE
Summit Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
13 Dec 2024 //
BUSINESSWIRE
Summit Therapeutics to Present at Upcoming Investor Conferences
26 Nov 2024 //
BUSINESSWIRE
Summit Therapeutics Reports Inducement Grants Under Nasdaq Rule
21 Nov 2024 //
BUSINESSWIRE
Merck signs up to $3.3 billion cancer drug deal with LaNova
16 Nov 2024 //
REUTERS
Summit Therapeutics Reports Q3 2024 Progress & Financial Results
30 Oct 2024 //
BUSINESSWIRE
Summit Therapeutics Q3 2024 Results & Operational Progress Call
23 Oct 2024 //
BUSINESSWIRE
Summit Therapeutics Reports Inducement Grants Under Nasdaq Rule
04 Oct 2024 //
BUSINESSWIRE
Summit Completes HARMONi Trial Enrollment For NSCLC Treatment
03 Oct 2024 //
BUSINESSWIRE
Ivonescimab Combo Shows Promise In CRC, TNBC, HNSCC at ESMO 2024
16 Sep 2024 //
BUSINESSWIRE
PESG Reports On Nuvectis Pharma`s NXP900
16 Sep 2024 //
BUSINESSWIRE
Summit Therapeutics Raises $235 Million
12 Sep 2024 //
BUSINESSWIRE
Akeso, Summit`s PD-1 Bispecific Outperforms Keytruda In Lung Cancer
09 Sep 2024 //
FIERCE PHARMA
Ivonescimab Outperforms Pembrolizumab In First-Line PD-L1+ NSCLC
08 Sep 2024 //
BUSINESSWIRE
Summit Therapeutics Reports Inducement Grants Under Nasdaq Rule
06 Sep 2024 //
BUSINESSWIRE
Two Ivonescimab Results For NSCLC To Be Presented At WCLC 2024
12 Aug 2024 //
PR NEWSWIRE
Summit Therapeutics Reports Inducement Grants
09 Aug 2024 //
BUSINESSWIRE
Summit Therapeutics Reports Q2 2024 Financial Results And Progress
06 Aug 2024 //
BUSINESSWIRE
Summit Therapeutics To Host Q2 2024 Results Call On August 6
29 Jul 2024 //
BUSINESSWIRE
Summit And MD Anderson Partner On Ivonescimab Development
25 Jul 2024 //
BUSINESSWIRE
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
03 Jul 2024 //
BUSINESSWIRE
Summit Appoints Jeff Huber, Transformational Google and GRAIL Executive
27 Jun 2024 //
BUSINESSWIRE
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
03 Jun 2024 //
BUSINESSWIRE
Ivonescimab HARMONi-A Trial Manuscript Published In JAMA
01 Jun 2024 //
BUSINESSWIRE
Ivonescimab-Chemo Combo Approved In China For EGFRm NSCLC After Chemo
01 Jun 2024 //
BUSINESSWIRE
Summit Reports Inducement Grants Per Nasdaq Rule
30 May 2024 //
BUSINESSWIRE
